(1) – Health Protection Agency. Salmonella Typhi and Salmonella Paratyphi Laboratory reports. Available at http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/Salmonella/EpidemiologicalData/salmDataTyphi/ accessed on 14/08/11
(2) – HPA. Typhoid Factsheet
(3) Dietrich G et al. Experience with registered mucosal vaccines. Vaccine 2003: 21: 678-683
(4) Guzman CA et al. Vaccines against typhoid fever. Vaccine 2006; 24: 3804-3811.
(5) Salerno-Gonclaves R et al. Characterization of CD8+ effector T cell responses in volunteers immunized with Salmonella enterica serovar Typhi strain Ty21a typhoid vaccine. J Immunol 2002; 169: 2196-2203.
(6) Sztein MB. Cell-Mediated immunity and antibody response elicited by attenuated Salmonella entericaserovar Typhi strains used as live oral vaccines in humans. Clin Infect Dis 2007; 45: 15-19
(7) – Levine MM. Typhoid Fever Vaccines, in Eds. Plotkin, S. Oreinstein W. Offit P. Vaccines. 5th edition Saunders Elsevier, 2008
(8) Vivotif® Summary of Product Characteristics, June 2010.
(9) Levine MM et al (eds.) Development of Vaccines and Drugs against Diarrhea. Lund, Sweden: Studenttliteratur; 1986; 90–101.
(10) Griot-Wenk ME et al. Low rate of spontaneously reported adverse drug reactions in a recent post-marketing surveillance for Vivotif Berna®. Italian J Tropical Medicine 2001; 6: 104–105.
(11) World Health Organization. Typhoid vaccines: WHO position paper. Weekly epidemiological record 2008; 83: 49–60.